Clinical outcomes and risk factors for severe COVID‐19 in patients with haematological disorders receiving chemo‐ or immunotherapy

Author:

Fox Thomas A.12ORCID,Troy‐Barnes Ethan1,Kirkwood Amy A.3,Chan Wei Yee14,Day James W.12ORCID,Chavda Selina J.14ORCID,Kumar Emil A.15,David Kate6,Tomkins Oliver1ORCID,Sanchez Emilie6,Scully Marie17ORCID,Khwaja Asim14,Lambert Jonathan17,Singer Mervyn78,Roddie Claire147,Morris Emma C.1279,Yong Kwee L.147ORCID,Thomson Kirsty J.17,Ardeshna Kirit M.17

Affiliation:

1. Department of Haematology University College London NHS Foundation Trust London UK

2. UCL Institute of Immunity and Transplantation UCL London UK

3. CR UK & UCL Cancer Trials Centre UCL Cancer Institute, UCL London UK

4. Department of Haematology UCL Cancer Institute London UK

5. Centre for Cancer Genomics and Computational Biology Barts Cancer Institute Queen Mary University of London London UK

6. Department of Clinical Virology University College London NHS Foundation Trust London UK

7. UCLH NIHR Biomedical Research Centre London UK

8. Bloomsbury Institute of Intensive Care Medicine UCL London UK

9. Department Immunology Royal Free London Hospitals NHS Foundation Trust London UK

Publisher

Wiley

Subject

Hematology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3